Type of information: Capital increase
Company: Harmonic Pharma (France)
Investors: Novacap (France)
Funding type: capital increase
- This capital increase will support Harmonic Pharma's development and future projects. Harmonic Pharma has developed a unique «pharmacological rediscovery ©» know-how based on polypharmacology. This innovative scientific approach aims to find new therapeutic applications to existing molecules. Beyond pharmaceutical applications, Harmonic Pharma's know-how can also be applied in other areas, such as in cosmetics where Novacap and Harmonic Pharma have also decided to partner together.
- Harmonic Pharma’s core business is based on the new paradigm of polypharmacology that consists in identifying the ensemble of biological targets linked to safe compounds in order to investigate their novel therapeutic applications. As an example, HPH112, developed in collaboration with the Institut Curie, is a promising drug candidate in combination with recent oncology treatments. In addition, thecompany offers its Pharmacological Rediscovery© platform to its partners/clients in health applications.
- • On December 4, 2017, Novacap, a global player in pharmaceutical synthesis and specialty chemicals, announced that it supports Harmonic Pharma through a capital increase in order to finance its development and future projects.
Therapeutic area: Technology - Services